Case Study: RTOs Leave Nothing to HAPpenstance

Overview:

In September 1998 the EPA promulgated a ruling in 40 CFR, imposing strict new standards to reduce emissions of toxic air pollutants from the manufacture of pharmaceutical products, including prescription and over-the-counter drugs. The agency’s rule was intended to reduce emissions of a number of air toxics and hazardous air pollutants (HAPs), including methylene chloride, methanol, toluene and HCI. It was estimated at the time that the ruling would reduce air toxins annually by approximately 24,000 tons or 65 percent from contemporaneous levels. The affected pharmaceutical manufacturing processes included chemical synthesis (drawing a drug’s active ingredient) and chemical formulation (producing a drug in its final form).